{
    "clinical_study": {
        "@rank": "1434", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "This study is a regulatory post-marketing surveillance in Japan, and it is a local\n      prospective and observational study of patients who have received Regorafenib for colorectal\n      cancer.\n\n      The objective of this study is to assess safety and effectiveness of Regorafenib using in\n      real clinical practice.\n\n      A total of 1,250 patients are to be enrolled and assessed in 6 months standard observational\n      period. At 12 months after the first administration of Regorafenib for confirmation of\n      efficacy information including treatment duration and survival status of the patient."
        }, 
        "brief_title": "Regorafenib Post-marketing Surveillance", 
        "completion_date": {
            "#text": "March 2021", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:Patients\n\n          -  who are determined to start Regorafenib/ STIVARGA treatment\n\n        Exclusion Criteria:\n\n          -  Patients who have previously received Regorafenib/ STIVARGA"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with unresectable, metastatic or recurrent colorectal cancer"
            }
        }, 
        "enrollment": {
            "#text": "1250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01843400", 
            "org_study_id": "16472", 
            "secondary_id": "STIVARGA-CRC-01"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patients treated with Regorafenib under practical manner for colorectal cancer.", 
            "intervention_name": "BAY73-4506_Regorafenib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Regorafenib", 
            "Colorectal Neoplasms"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Japan"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Drug Use Investigation of Regorafenib/ STIVARGA for Unresectable, Metastatic or Recurrent Colorectal Cancer", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of patients with adverse drug reactions (ADRs) from the first administration of regorafenib", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Number of patients with serious adverse events(SAEs)  from the first administration of regorafenib.", 
                "safety_issue": "Yes", 
                "time_frame": "up to 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01843400"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Determination of patient's background  to affect the safety and efficacy of Regorafenib using standard observational survey and follow-up survey", 
            "safety_issue": "No", 
            "time_frame": "baseline"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2014"
    }
}